Platform – KIFFIK Biomedical Inc.

The human body is constantly communicating — through biomarkers, rhythms, and subtle biochemical signals. KIFFIK’s platform is designed to listen and interpret those signals through interstitial fluid (ISF), offering insight before symptoms appear.

An intelligent system, amplified

*The KIFFIK Lab is not FDA cleared. For investigational use only.

A new kind of health platform.

No blood.
No clinics.
No waiting.

Built on non-invasive ISF access, our platform has the ability to transform biomarker-rich data into actionable diagnostics. It’s not just about collecting information — it’s about translating the body’s own language into early, personalized decisions that improve outcomes.

What sets the KIFFIK platform apart:

Seamless ISF Access

At the foundation of the platform is patented electroporation technology that enables non-invasive, repeatable access to ISF. This eliminates the need for blood draws and reduces patient burden — creating a new diagnostic experience that’s precise, comfortable, and scalable.

Biomarker Intelligence Layer

The platform goes beyond raw data. ISF samples are interpreted through targeted assays and a biomarker-aware data layer that translates biological signals into clinical insight — supporting faster, more informed decisions.

Built for Versatility

The architecture is modular, allowing for expansion across clinical areas and patient needs. Whether deployed at the point of care or in a research setting, the platform is engineered to scale — without compromising on precision or safety.

Looking ahead:

Real time, dynamic health insight.

The next evolution of the KIFFIK platform will integrate multiplexed sensor systems and AI-driven analytics — enabling continuous, real-time analysis of multiple biomarkers at once. This shift will move diagnostics beyond the lab and into everyday life, where insights are dynamic, contextual, and proactive.

With the ability to process multiple biological signals simultaneously and interpret them through intelligent algorithms, the platform will support:

Continuous physiological monitoring

Dynamic baseline modeling and trend recognition

Predictive health alerts and adaptive diagnostics

This is diagnostics as an intelligent companion — not just a test.

Use cases:

Colorectal Cancer

Learn more ➝

Traumatic Brain Injury

Learn more ➝

Skin Health

Learn more ➝

Sepsis

Learn more ➝

ISF & Biomarker Research

Learn more ➝

Prostate Cancer

Learn more ➝

PolyTrauma

Learn more ➝

Women's Health

Learn more ➝

Join us at the forefront of
diagnostic innovation

We’re partnering with leading scientists, institutions, and companies interested in conducting clinical research using ISF biomarkers, with a focus on personalized biomarker discovery and novel product development.

Partner WIth Us

Dermatology: Non-invasive assessment of skin inflammation, disease flares (e.g., eczema, psoriasis), and potentially early indicators of melanoma or other skin cancers

Beauty & Wellness: Real-time monitoring of skin barrier integrity, hydration, oxidative stress, and treatment response for personalized skincare routines

A new kind of health platform.

No blood. No clinics. No waiting.

What sets the KIFFIK platform apart:

Seamless ISF Access

Biomarker Intelligence Layer

Built for Versatility

Looking ahead:

Real time, dynamic health insight.

This is diagnostics as an intelligent companion — not just a test.

Use cases:

Colorectal Cancer

Traumatic Brain Injury

Skin Health

Sepsis

ISF & Biomarker Research

Prostate Cancer

PolyTrauma

Women's Health

Join us at the forefront of diagnostic innovation

Navigation

FOLLOW US

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Estradiol (E2)

Luteinizing Hormone (LH)

Progesterone

Follicle-Stimulating Hormone (FSH)

Anti-Müllerian Hormone (AMH)

Hormonal health shouldn’t be a guessing game. With KIFFIK, women can see their cycle, and their care, more clearly than ever before.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Interleukin-6 (IL-6)

S100B (neurotrauma indicator)

Lactate (tissue hypoxia)

D-dimer (coagulation dysfunction)

Myoglobin (muscle damage)

TNF-α (systemic inflammation)

When every second counts, insight can’t wait for the hospital. KIFFIK’s platform is designed to move with the mission — delivering data where it’s needed most.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Prostate-Specific Antigen (PSA)

PCA3 (Prostate Cancer Antigen 3)

Alpha-methylacyl-CoA racemase (AMACR)

Circulating tumor DNA (ctDNA) for mutation profiling

Interleukin-8 (IL-8) and other inflammation markers

Continuous insight without constant disruption, KIFFIK’s platform enables smarter, patient-centered care for prostate cancer across the spectrum of disease.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

IL-6, CRP (inflammatory signaling)

Adiponectin, leptin (metabolic regulation)

VEGF, IL-8 (oncogenic pathways)

S100B, GFAP (neuroinflammatory injury)

Every breakthrough begins with better data. KIFFIK gives researchers a new lens on human biology, continuously, painlessly, and in real time.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Procalcitonin (PCT)

C-reactive protein (CRP)

Interleukin-6 (IL-6)

TNF-α (Tumor Necrosis Factor-alpha)

Lactate

When sepsis moves fast, we have to move faster. KIFFIK’s platform could help detect the warning signs before symptoms spiral.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Interleukin-1α (IL-1α)

Interleukin-8 (IL-8)

TNF-α

MMP-9 (Matrix metalloproteinase-9)

Reactive oxygen species (ROS)

No blood.
No clinics.
No waiting.

Join us at the forefront of
diagnostic innovation